We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
112 hedge funds and large institutions have $81.8M invested in Lyell Immunopharma in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
7% more funds holding
Funds holding: 105 → 112 (+7)
0.01% more ownership
Funds ownership: 2.57% → 2.58% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
15% less capital invested
Capital invested by funds: $95.9M → $81.8M (-$14.1M)
33% less call options, than puts
Call options by funds: $2K | Put options by funds: $3K
36% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 36
Holders
112
Holders Change
+7
Holders Change %
+6.67%
% of All Funds
1.5%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
14
Increased
23
Reduced
36
Closed
7
Calls
$2K
Puts
$3K
Net Calls
-$1K
Net Calls Change
-$2K
Top Buyers
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$1.99M |
| 2 |
Millennium Management
New York
|
-$560K |
| 3 |
D.E. Shaw & Co
New York
|
-$545K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$506K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$462K |
